These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 26750638

  • 1. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
    Sueda T, Sakai D, Kawamoto K, Konno M, Nishida N, Koseki J, Colvin H, Takahashi H, Haraguchi N, Nishimura J, Hata T, Takemasa I, Mizushima T, Yamamoto H, Satoh T, Doki Y, Mori M, Ishii H.
    Sci Rep; 2016 Jan 11; 6():18949. PubMed ID: 26750638
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F.
    Cancer Res; 2012 Feb 01; 72(3):779-89. PubMed ID: 22180495
    [Abstract] [Full Text] [Related]

  • 3. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
    Zhang P, Kawakami H, Liu W, Zeng X, Strebhardt K, Tao K, Huang S, Sinicrope FA.
    Mol Cancer Res; 2018 Mar 01; 16(3):378-389. PubMed ID: 29233910
    [Abstract] [Full Text] [Related]

  • 4. V600EBRAF Inhibition Induces Cytoprotective Autophagy through AMPK in Thyroid Cancer Cells.
    Jiménez-Mora E, Gallego B, Díaz-Gago S, Lasa M, Baquero P, Chiloeches A.
    Int J Mol Sci; 2021 Jun 03; 22(11):. PubMed ID: 34204950
    [Abstract] [Full Text] [Related]

  • 5. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
    Goulielmaki M, Koustas E, Moysidou E, Vlassi M, Sasazuki T, Shirasawa S, Zografos G, Oikonomou E, Pintzas A.
    Oncotarget; 2016 Feb 23; 7(8):9188-221. PubMed ID: 26802026
    [Abstract] [Full Text] [Related]

  • 6. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE.
    Matrix Biol; 2015 Oct 23; 48():66-77. PubMed ID: 25989506
    [Abstract] [Full Text] [Related]

  • 7. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
    Tang Z, Yuan X, Du R, Cheung SH, Zhang G, Wei J, Zhao Y, Feng Y, Peng H, Zhang Y, Du Y, Hu X, Gong W, Liu Y, Gao Y, Liu Y, Hao R, Li S, Wang S, Ji J, Zhang L, Li S, Sutton D, Wei M, Zhou C, Wang L, Luo L.
    Mol Cancer Ther; 2015 Oct 23; 14(10):2187-97. PubMed ID: 26208524
    [Abstract] [Full Text] [Related]

  • 8. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
    Kotani H, Adachi Y, Kitai H, Tomida S, Bando H, Faber AC, Yoshino T, Voon DC, Yano S, Ebi H.
    Oncogene; 2018 Mar 23; 37(13):1775-1787. PubMed ID: 29348459
    [Abstract] [Full Text] [Related]

  • 9. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N.
    Proc Natl Acad Sci U S A; 2010 Aug 17; 107(33):14903-8. PubMed ID: 20668238
    [Abstract] [Full Text] [Related]

  • 10. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M.
    Clin Cancer Res; 2007 Feb 15; 13(4):1341-9. PubMed ID: 17317846
    [Abstract] [Full Text] [Related]

  • 11. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAFV600E mutant cancer.
    Hong SP, Ahn SK.
    Life Sci; 2017 Aug 15; 183():37-44. PubMed ID: 28645859
    [Abstract] [Full Text] [Related]

  • 12. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

  • 13. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
    Nakamura Y, Hattori N, Iida N, Yamashita S, Mori A, Kimura K, Yoshino T, Ushijima T.
    Cancer Lett; 2017 Aug 28; 402():100-109. PubMed ID: 28576751
    [Abstract] [Full Text] [Related]

  • 14. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.
    Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, Schostack K, Simcox ME, Heimbrook D, Bollag G, Su F.
    Cancer Res; 2010 Jul 01; 70(13):5518-27. PubMed ID: 20551065
    [Abstract] [Full Text] [Related]

  • 15. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
    Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA.
    Mol Cancer Ther; 2016 Dec 01; 15(12):3015-3027. PubMed ID: 27765849
    [Abstract] [Full Text] [Related]

  • 16. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
    Räsänen K, Dang KX, Mustonen H, Ho TH, Lintula S, Koistinen H, Stenman UH, Haglund C, Stenman J.
    Mol Oncol; 2018 Feb 01; 12(2):224-238. PubMed ID: 29193645
    [Abstract] [Full Text] [Related]

  • 17. BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma.
    Dizdar L, Werner TA, Drusenheimer JC, Möhlendick B, Raba K, Boeck I, Anlauf M, Schott M, Göring W, Esposito I, Stoecklein NH, Knoefel WT, Krieg A.
    Int J Cancer; 2019 Mar 15; 144(6):1379-1390. PubMed ID: 30144031
    [Abstract] [Full Text] [Related]

  • 18. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
    Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA.
    Cancer Discov; 2012 Mar 15; 2(3):227-35. PubMed ID: 22448344
    [Abstract] [Full Text] [Related]

  • 19. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
    McKinley ET, Smith RA, Zhao P, Fu A, Saleh SA, Uddin MI, Washington MK, Coffey RJ, Manning HC.
    J Nucl Med; 2013 Mar 15; 54(3):424-30. PubMed ID: 23341544
    [Abstract] [Full Text] [Related]

  • 20. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, Oliveira C, Seruca R.
    J Pathol; 2008 Feb 15; 214(3):320-7. PubMed ID: 18098337
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.